CN116077557A - Composition for treating alopecia areata and application thereof - Google Patents
Composition for treating alopecia areata and application thereof Download PDFInfo
- Publication number
- CN116077557A CN116077557A CN202310027290.8A CN202310027290A CN116077557A CN 116077557 A CN116077557 A CN 116077557A CN 202310027290 A CN202310027290 A CN 202310027290A CN 116077557 A CN116077557 A CN 116077557A
- Authority
- CN
- China
- Prior art keywords
- parts
- alopecia areata
- composition
- mixture
- treating alopecia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 110
- 208000004631 alopecia areata Diseases 0.000 title claims abstract description 88
- 239000003814 drug Substances 0.000 claims abstract description 92
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 47
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 45
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000002378 acidificating effect Effects 0.000 claims abstract description 20
- 230000003779 hair growth Effects 0.000 claims abstract description 20
- 230000001737 promoting effect Effects 0.000 claims abstract description 20
- 239000000126 substance Substances 0.000 claims abstract description 20
- 235000019445 benzyl alcohol Nutrition 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims description 15
- 241001289529 Fallopia multiflora Species 0.000 claims description 10
- 241000112528 Ligusticum striatum Species 0.000 claims description 10
- 241000301400 Trogopterus Species 0.000 claims description 10
- 210000003608 fece Anatomy 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 10
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 9
- 240000007551 Boswellia serrata Species 0.000 claims description 9
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 9
- 239000004863 Frankincense Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 240000000249 Morus alba Species 0.000 claims description 6
- 235000008708 Morus alba Nutrition 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 5
- 229960004889 salicylic acid Drugs 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 36
- 210000003780 hair follicle Anatomy 0.000 abstract description 13
- 208000005392 Spasm Diseases 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 229940126585 therapeutic drug Drugs 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
- 210000004209 hair Anatomy 0.000 description 9
- 201000004384 Alopecia Diseases 0.000 description 8
- 231100000360 alopecia Toxicity 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010001767 Alopecia universalis Diseases 0.000 description 4
- 208000032775 alopecia universalis congenita Diseases 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010001766 Alopecia totalis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960002311 dithranol Drugs 0.000 description 2
- 210000004709 eyebrow Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920000175 Pistacia lentiscus Polymers 0.000 description 1
- 240000002924 Platycladus orientalis Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- -1 phenol) Chemical compound 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000007371 visceral function Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a composition for treating alopecia areata and application thereof, and belongs to the technical field of alopecia areata treatment, wherein the composition comprises the following components in parts by weight: 2-50 parts of acidic substance, 5-30 parts of diethyl ether, 5-30 parts of ethanol, 5-20 parts of glycerol and 5-20 parts of benzyl alcohol. The invention solves the hair follicle spasm problem of the alopecia areata part by the mutual synergy of the components with the specific proportion, and is beneficial to promoting the absorption of hair follicle to hair growth nutrient substances and effective components of therapeutic drugs. When the composition is applied to preparing the medicament for treating alopecia areata, if the composition is matched with a traditional Chinese medicine composition capable of promoting hair growth, the problems that the conventional alopecia areata treatment method is long in treatment course, low in cure rate, large in side effect and incapable of timely judging whether the treatment effect is good or not by a patient can be effectively solved.
Description
Technical Field
The invention relates to the technical field of alopecia areata treatment, in particular to a composition for treating alopecia areata and application thereof.
Background
Alopecia Areata (AA), commonly known as "shaving head", is a skin disease characterized by sudden localized alopecia areata, in which the hair rapidly drops off at the lesions, and is circular or irregular, and a few people can drop off all the hair, known as alopecia totalis. Modern medicine suggests that the etiology and pathogenesis of this disease may be related to autoimmune, genetic, mental, microcirculation disorders, other visceral functions, and endocrine disorders.
The main method for treating alopecia areata at home and abroad at present comprises the following steps:
1. the common external medicine is as follows:
(1) Minoxidil; 5% minoxidil cream or solvent, applied 1 or 2 times daily, may be associated with its vasodilation effect.
(2) Anthralin; 0.5 to 1 percent of anthralin ointment or cream is a primary stimulant. It is applied externally 1 to several times daily to limit the appearance of mild dermatitis on the local skin.
(3) A contact sensitizer; diphenyl propenone (DCP) is most commonly used.
(4) Glucocorticoids; potent hormones are administered topically or encapsulated. 0.05% dexamethasone and 50% dimethyl sulfoxide solution have better curative effect than cream and the like when being externally used.
2. The usual internal medications are as follows:
(1) Glucocorticoids; prednisone is taken orally, gradually reduced after several weeks, and then maintained at a small dose for 6 months. The glucocorticoid has good effect, but has great side effect, and is easy to relapse after stopping the medicine, so the glucocorticoid is not used as a conventional therapy. But can be used for treating acute alopecia areata to avoid the development of total alopecia or alopecia universalis.
(2) Cyclosporine; the treatment course is 6-12 months. Some cases are effective, e.g. no effect stops after 4 months.
(3) Thymopentin: intramuscular injection was continued for 3 weeks.
(4) Vasodilators: niacin is orally administered.
3. A local injection method;
local injection of glucocorticoids is suitable for small-scale alopecia, or for important cosmetic parts (such as eyebrows) of patients with alopecia universalis. The alopecia area can be directly injected, or the periphery of the alopecia area can be injected, so as to control the continuous expansion of the alopecia area. Care is taken to avoid local skin atrophy and sagging that may be caused.
4. Nerve block therapy;
the occipital nerve is occluded, and after the nerve is occluded, the skin temperature in the dominant region increases, which is beneficial to hair regeneration.
At present, although a plurality of methods for treating alopecia areata at home and abroad exist, the treatment methods at least have the following problems:
(1) The treatment course is long.
(2) The treatment effect varies from person to person and the patient cannot judge the treatment effect in time.
(3) The problems of large side effect and easy repeated attack are treated.
(4) Low cure rate.
Disclosure of Invention
The invention aims to provide a composition for treating alopecia areata and application thereof, and aims to solve the technical problems that the conventional alopecia areata treatment method is long in treatment course, low in cure rate, large in side effect and incapable of timely judging whether the treatment effect is good or not by a patient.
In a first aspect, embodiments of the present application provide a composition for treating alopecia areata, the composition comprising, in parts by weight:
2-50 parts of acidic substance, 5-30 parts of diethyl ether, 5-30 parts of ethanol, 5-20 parts of glycerol and 5-20 parts of benzyl alcohol.
Further, the composition comprises, in parts by weight:
20-50 parts of acidic substances, 20-30 parts of diethyl ether, 10-20 parts of ethanol, 5-10 parts of glycerol and 5-10 parts of benzyl alcohol.
Further, the acidic substance includes at least one of carbolic acid, salicylic acid, and fruit acid.
In a second aspect, embodiments of the present application provide the use of the composition of the first aspect in the preparation of a medicament for treating alopecia areata.
In a third aspect, embodiments of the present application provide a medicament for treating alopecia areata, the medicament comprising:
(i) The composition of any one of the first aspects; and
(ii) A Chinese medicinal composition for promoting hair growth.
Further, the traditional Chinese medicine composition comprises the following components in parts by weight:
10-30 parts of polygonum multiflorum, 10-30 parts of cortex mori radicis, 5-20 parts of frankincense, 10-20 parts of ligusticum wallichii and 5-20 parts of trogopterus dung.
Further, the traditional Chinese medicine composition comprises the following components in parts by weight:
30 parts of polygonum multiflorum, 30 parts of white mulberry root-bark, 20 parts of frankincense, 10 parts of ligusticum wallichii and 10 parts of trogopterus dung.
In a fourth aspect, an embodiment of the present application provides a method for preparing a medicament for treating alopecia areata according to any one of the third aspects, the method comprising:
mixing acidic substances, diethyl ether, ethanol, glycerol and benzyl alcohol according to a proportion to obtain a first mixture;
mixing the components in the traditional Chinese medicine composition according to a proportion to obtain a second mixture;
and mixing the first mixture and the second mixture, processing, and filtering to obtain the medicine for treating alopecia areata.
Further, the steps of mixing and processing the first mixture and the second mixture, and filtering to obtain the medicine for treating alopecia areata comprise the following steps:
and standing the fully dissolved first mixture for 24-48 hours, then adding the second mixture, fully stirring, stirring once every 12-16 days, sealing, standing for 80-100 days, and filtering to obtain the medicine for treating alopecia areata.
Compared with the prior art, the scheme provided by the embodiment of the application has at least the following beneficial effects:
the embodiment of the application provides a composition for treating alopecia areata, which comprises 2-50 parts of acidic substances, 5-30 parts of diethyl ether, 5-30 parts of ethanol, 5-20 parts of glycerol and 5-20 parts of benzyl alcohol, and through mutual cooperation of the components in the specific proportion, the problem of hair follicle spasm at the alopecia areata is relieved by the combined action of the components, and the absorption of hair follicle to hair growth nutrients and active ingredients of therapeutic drugs is promoted. When the composition is applied to preparing the medicament for treating alopecia areata, if the composition is matched with a traditional Chinese medicine composition capable of promoting hair growth, the problems that the conventional alopecia areata treatment method is long in treatment course, low in cure rate, large in side effect and incapable of timely judging whether the treatment effect is good or not by a patient can be effectively solved.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings that are needed in the embodiments will be briefly described below, it being understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and other related drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
Fig. 1 is a schematic flow chart of a preparation method of a drug for treating alopecia areata according to an embodiment of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions of the embodiments of the present invention will be clearly and completely described below. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
It should be noted that, in the case of no conflict, the embodiments and features in the embodiments may be combined with each other. The present invention will be described in detail with reference to specific examples.
The general idea of the technical scheme provided by the embodiment of the invention is as follows:
in a first aspect, embodiments of the present application provide a composition for treating alopecia areata, the composition comprising, in parts by weight:
2-50 parts of acidic substance, 5-30 parts of diethyl ether, 5-30 parts of ethanol, 5-20 parts of glycerol and 5-20 parts of benzyl alcohol.
The embodiment of the application provides a composition for treating alopecia areata, which comprises 2-50 parts of acidic substances, 5-30 parts of diethyl ether, 5-30 parts of ethanol, 5-20 parts of glycerol and 5-20 parts of benzyl alcohol, and through mutual cooperation of the components in the specific proportion, the problem of hair follicle spasm at the alopecia areata is relieved by the combined action of the components, and the absorption of hair follicle to hair growth nutrients and active ingredients of therapeutic drugs is promoted. When the composition is applied to preparing the medicament for treating alopecia areata, if the composition is matched with a traditional Chinese medicine composition capable of promoting hair growth, the problems that the conventional alopecia areata treatment method is long in treatment course, low in cure rate, large in side effect and incapable of timely judging whether the treatment effect is good or not by a patient can be effectively solved.
The effects of the components in the composition for treating alopecia areata provided by the embodiment of the application are as follows:
1. acidic substance: the main function is to remove the cuticle of the follicular orifice, so that the medicine can permeate into the follicular orifice, and the effects of diminishing inflammation and sterilizing are achieved.
2. Diethyl ether: relieving spasm and relieving pain; deep into hair follicle thoroughly relieves the symptoms of cramps and reduces the feeling of pain caused by removal of the stratum corneum.
3. Benzyl alcohol: because benzyl alcohol has a certain anesthetic effect, penetration into hair follicles can have a certain antispasmodic effect, and also has the effect of eliminating inflammation.
4. Ethanol: since benzyl alcohol is dissolved in ethanol, the solubility of benzyl alcohol and the like is increased, so that several mixtures are sufficiently dissolved.
5. Glycerol: the function is to protect the local skin from moisture and chapping.
Therefore, the acid substance, ethanol, diethyl ether, benzyl alcohol and glycerol with the specific proportions are matched for use, and the effects are achieved through combined action.
As an embodiment of the examples herein, the composition comprises, in parts by weight:
20-50 parts of acidic substances, 20-30 parts of diethyl ether, 10-20 parts of ethanol, 5-10 parts of glycerol and 5-10 parts of benzyl alcohol.
The application further adopts the acid substance, ethanol, diethyl ether, benzyl alcohol and glycerol with the specific proportion to carry out the matched use, and the effect is better.
As an embodiment of the examples herein, the acidic substance includes at least one of carbolic acid, salicylic acid, and fruit acid.
The application further adopts acidic substances such as carbolic acid, salicylic acid and fruit acid, and the main effect is to remove the cuticle of follicular orifice, lets the medicine can permeate into, plays the effect of diminishing inflammation and sterilizing simultaneously, and above-mentioned effect is better. In some embodiments, fruit acids such as glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid, and the like may be used.
In a second aspect, embodiments of the present application provide the use of the composition of the first aspect in the preparation of a medicament for treating alopecia areata.
When the composition disclosed in the first aspect of the application is applied to the preparation of the medicament for treating alopecia areata, if the composition is matched with a traditional Chinese medicine composition capable of promoting hair growth, the problems that the conventional alopecia areata treatment method is long in treatment course, low in cure rate, large in side effect and incapable of timely judging whether the treatment effect is good or not by a patient can be effectively solved.
In a third aspect, embodiments of the present application provide a medicament for treating alopecia areata, the medicament comprising:
(i) The composition of any one of the first aspects; and
(ii) A Chinese medicinal composition for promoting hair growth.
The embodiment of the present application provides a medicament for treating alopecia areata, which is realized based on the composition according to any one of the first aspect, and because the medicament adopts a part or all of the technical schemes of the medicament, the medicament at least has all the beneficial effects brought by the technical schemes of the embodiment, and the description is omitted herein.
The traditional Chinese medicine composition for promoting hair growth specifically refers to a traditional Chinese medicine composition capable of providing nutrition for hair growth and/or playing a role in promoting hair growth. In some specific embodiments, the traditional Chinese medicine composition may be as disclosed in the first prior art (chinese patent CN104800263a, a traditional Chinese medicine composition for treating alopecia areata, and a preparation method and application thereof), and the traditional Chinese medicine composition comprises the following components in parts by weight: 30 parts of safflower, 30 parts of biota orientalis and 30 parts of ginseng leaf; or a traditional Chinese medicine composition which is disclosed in the second prior art (Chinese patent CN114984144A, a traditional Chinese medicine composition for treating alopecia areata) and consists of 20 parts of semen cuscutae, 15 parts of Chinese angelica, 10 parts of prepared fleece-flower root, 10 parts of fructus psoraleae, 15 parts of medlar, 20 parts of prepared rehmannia root, 15 parts of achyranthes root, 15 parts of Chinese yam, 15 parts of fructus corni, 12 parts of rhizoma alismatis, 15 parts of poria cocos, 10 parts of gastrodia elata, 10 parts of radix sileris and 15 parts of cortex moutan.
In some embodiments, the weight ratio of the composition of any of the first aspects to the hair growth promoting traditional Chinese medicine composition may be (3-5): (1-2) or the like, such as 3:1, 4:1, 5:1, 5:2 or the like.
As an implementation mode of the embodiment of the application, the traditional Chinese medicine composition comprises the following components in parts by weight:
10-30 parts of polygonum multiflorum, 10-30 parts of cortex mori radicis, 5-20 parts of frankincense, 10-20 parts of ligusticum wallichii and 5-20 parts of trogopterus dung.
The traditional Chinese medicine composition comprising 10-30 parts of polygonum multiflorum, 10-30 parts of white mulberry root-bark, 5-20 parts of frankincense, 10-20 parts of ligusticum wallichii and 5-20 parts of trogopterus dung has better synergistic effect with the composition according to any one of the first aspect, and can effectively solve the problems that the treatment course is long, the cure rate is low, the side effect is large and the treatment effect cannot be judged by patients in time in the existing alopecia areata treatment method.
The functions of the components in the traditional Chinese medicine composition are as follows:
1. polygonum multiflorum Thunb: increasing hair nutrition and promoting hair growth.
2. Cortex Mori: increasing hair nutrition and promoting hair growth.
3. Mastic gum: promoting blood circulation.
4. Ligusticum wallichii: promoting blood circulation.
5. Trogopterus dung: promoting blood circulation and relieving pain.
Therefore, the polygonum multiflorum, the white mulberry root-bark, the frankincense, the ligusticum wallichii and the trogopterus dung which are prepared in the specific proportion are combined into the traditional Chinese medicine composition, and the traditional Chinese medicine composition is matched with the composition in any one of the first aspect for use, so that the effect of effectively treating alopecia areata is achieved by solving the problems of hair follicle spasm and hair follicle nutrition supply and absorption.
As an implementation mode of the embodiment of the application, the traditional Chinese medicine composition comprises the following components in parts by weight:
30 parts of polygonum multiflorum, 30 parts of white mulberry root-bark, 20 parts of frankincense, 10 parts of ligusticum wallichii and 10 parts of trogopterus dung.
The application adopts the polygonum multiflorum, the white mulberry root-bark, the frankincense, the ligusticum wallichii and the trogopterus dung which are prepared into the traditional Chinese medicine composition in the specific proportion, and the synergistic effect of the traditional Chinese medicine composition and the composition in any one of the first aspect is better.
In a fourth aspect, an embodiment of the present application provides a method for preparing a medicament for treating alopecia areata according to any one of the third aspects, as shown in fig. 1, where the method includes:
mixing acidic substances, diethyl ether, ethanol, glycerol and benzyl alcohol according to a proportion to obtain a first mixture;
mixing the components in the traditional Chinese medicine composition according to a proportion to obtain a second mixture;
and mixing the first mixture and the second mixture, processing, and filtering to obtain the medicine for treating alopecia areata.
The embodiment of the application provides the preparation method of the medicine for treating alopecia areata, which is simple to operate, does not need extra specific equipment, and is characterized in that the first mixture and the second mixture are mixed and processed and filtered, and the obtained filtrate is the medicine.
As an implementation manner of the embodiment of the present application, the steps of mixing and processing the first mixture and the second mixture, and filtering to obtain the medicine for treating alopecia areata include:
and standing the fully dissolved first mixture for 24-48 hours, then adding the second mixture, fully stirring, stirring once every 12-16 days, sealing, standing for 80-100 days, and filtering to obtain the medicine for treating alopecia areata.
In addition, the application method of the medicine for treating alopecia areata provided by the embodiment of the application is very simple, and specifically can include:
1. firstly, medical alcohol is used for wiping the alopecia areata and the alopecia part for disinfection.
2. The application provides a little wipe the alopecia areata hair loss position once slightly with medical cotton swab dips in the medicine that is used for treating alopecia areata that this application provided, stay ten seconds, then dip in the medicine again with new cotton swab and paint in the alopecia areata position, with medical gauze repeatedly and evenly wipe, it repeats the process of second time to dip in the medicine for the third time after ten seconds to stay, see the scalp colour at this time and begin to turn white, the follicular orifice can stop clearly, if not clearly repeat once more can, stay for one minute the back with medical gauze clear the residue of alopecia areata position can.
In summary, the present invention at least solves the following problems for patients suffering from alopecia areata:
1. the treatment cycle is long; the invention does not need oral medicine, is directly applied to the alopecia areata part by local external application, and can be solved in a few minutes, and has the advantages of simple operation, convenient use, quick and obvious effect and short treatment process.
2. The curative effect is not definite; the invention can clearly tell the patient that the hair cannot grow out by observing the skin change, and the growth cycle can also be determined, and the hair can grow out by clearly seeing the penetration of the hair follicle, and the normal hair can naturally grow out within 7-90 days.
3. The problem of large side effects; the invention has the advantages of local treatment, only removal of horny layer, no atrophy and depression, no hormone influence on liver and kidney functions and small side effect.
4. The problem of easy recurrence; the invention expands a little range in the smearing process, has good treatment effect, and solves the problem that the expansion of the alopecia areata range is easy to repeat.
It should be noted that:
1. five days after the treatment of the alopecia areata part, the bathing, the soaking, and the like are not needed, so as to prevent bacteria from entering hair follicles to cause infection.
2. The medicine for treating alopecia areata provided by the embodiment of the application has poor effects on alopecia totalis and alopecia universalis.
3. The medicine for treating alopecia areata provided by the embodiment of the application is not suitable for eyebrow, beard, body hair and other parts.
The features and capabilities of the present invention are described in further detail below in connection with the examples.
Examples 1 to 9 and comparative examples 1 to 5 provide a composition for treating alopecia areata, and the specific amounts of each of the components in examples 1 to 5 and comparative examples 1 to 5 in parts by weight (unit: g) are shown in Table 1; wherein the acidic material in examples 1-5, example 9 and comparative examples 1-5 is carbolic acid (i.e., phenol), the acidic material in example 6 is salicylic acid, and the acidic material in example 8 is citric acid.
TABLE 1
Examples 10 to 20 and comparative examples 6 to 10 provide a medicament for treating alopecia areata, wherein: examples 10 to 18 provide a medicament for treating alopecia areata, and the compositions for treating alopecia areata, which are provided in examples 1 to 9, are used together with a traditional Chinese medicine composition capable of promoting hair growth, respectively, so as to obtain the medicament for treating alopecia areata; examples 19 and 20 the composition for treating alopecia areata provided in example 9 was used in combination with a hair growth promoting Chinese medicinal composition; comparative examples 1 to 5 provide a composition for treating alopecia areata, which is used as comparative examples 6 to 10 in combination with a Chinese medicinal composition for promoting hair growth, respectively. The medicaments in examples 10 to 20 and comparative examples 6 to 10 comprise, in parts by weight (unit: g):
(i) Any of examples 1-9 and comparative examples 1-5 provide a composition for treating alopecia areata; (ii) a Chinese medicinal composition for promoting hair growth.
The specific amounts of the components in examples 10 to 20 and comparative examples 6 to 10 are shown in Table 2.
TABLE 2
The preparation method of the drug for treating alopecia areata in the above examples 10 to 20 and comparative examples 6 to 10 comprises:
mixing the composition for treating alopecia areata according to a proportion to obtain a first mixture;
mixing and crushing the components in the traditional Chinese medicine composition according to a proportion to obtain a second mixture;
and standing the fully dissolved first mixture for 24 hours, mixing the first mixture and the second mixture according to the weight ratio of 3:1, fully stirring, stirring once every 15 days, sealing, standing for 90 days, filtering, and collecting filtrate to obtain the medicine for treating alopecia areata.
Test case
In this example, the drugs for treating alopecia areata provided in examples 10 to 20 and comparative examples 6 to 10 were subjected to treatment effect test.
The testing method comprises the following steps: the medicine is rubbed on the alopecia areata part of the patient, the medicine is rubbed once in the first day, the medicine is not used for the second time if the hair follicle is observed to grow out by naked eyes after 20 days, and the medicine is rubbed again after 30 days apart if no new hair grows out. Each wiping process is as follows:
1. firstly, wiping the alopecia areata and the alopecia part of the patient with medical alcohol for disinfection.
2. The medicine for treating alopecia areata is dipped with a medical cotton swab, the alopecia areata is gently wiped once (the cotton swab is fully wetted), after the medicine is stopped for ten seconds, the medicine is dipped with a new cotton swab again and smeared on the alopecia areata, the wiping process is repeated for 3 times, and finally the medicine gauze is used for removing residues on the alopecia areata after the medicine is stopped for one minute.
Test object: 240 qualified subjects suffering from alopecia areata (at least 30% of scalp area affected, patients without alopecia totalis and alopecia universalis) were randomly divided into 16 groups of 15 persons each, each group being rubbed with the drugs for treating alopecia areata provided in examples 10 to 20 and comparative examples 6 to 10, respectively.
The test results after the subjects rubbed the drugs for treating alopecia areata provided in examples 10 to 20 and comparative examples 6 to 10 are shown in table 3.
TABLE 3 Table 3
Various embodiments of the present application may exist in a range of forms; it should be understood that the description in a range format is merely for convenience and brevity and should not be interpreted as a rigid limitation on the scope of the application. It is therefore to be understood that the range description has specifically disclosed all possible sub-ranges and individual values within that range. For example, it should be considered that a description of a range from 1 to 6 has specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5, and 6, wherever applicable. In addition, whenever a numerical range is referred to herein, it is meant to include any reference number (fractional or integer) within the indicated range.
In addition, in the description of the present application, the terms "include", "comprise", "comprising" and the like mean "including but not limited to". Relational terms such as "first" and "second", and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the invention is not intended to limit the scope of the invention, as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Claims (9)
1. A composition for treating alopecia areata, which is characterized by comprising, in parts by weight:
2-50 parts of acidic substance, 5-30 parts of diethyl ether, 5-30 parts of ethanol, 5-20 parts of glycerol and 5-20 parts of benzyl alcohol.
2. The composition according to claim 1, characterized in that it comprises, in parts by weight:
20-50 parts of acidic substances, 20-30 parts of diethyl ether, 10-20 parts of ethanol, 5-10 parts of glycerol and 5-10 parts of benzyl alcohol.
3. The composition of claim 1 or 2, wherein the acidic substance comprises at least one of stonecarbonic acid, salicylic acid, and fruit acid.
4. Use of a composition according to any one of claims 1 to 3 for the preparation of a medicament for the treatment of alopecia areata.
5. A medicament for treating alopecia areata, the medicament comprising:
(i) A composition according to any one of claims 1 to 3; and
(ii) A Chinese medicinal composition for promoting hair growth.
6. The medicine according to claim 5, wherein the Chinese medicinal composition comprises, in parts by weight:
10-30 parts of polygonum multiflorum, 10-30 parts of cortex mori radicis, 5-20 parts of frankincense, 10-20 parts of ligusticum wallichii and 5-20 parts of trogopterus dung.
7. The medicament according to claim 5 or 6, wherein the Chinese medicinal composition comprises, in parts by weight:
30 parts of polygonum multiflorum, 30 parts of white mulberry root-bark, 20 parts of frankincense, 10 parts of ligusticum wallichii and 10 parts of trogopterus dung.
8. A method for preparing the medicament for treating alopecia areata according to any one of claims 5 to 7, comprising:
mixing acidic substances, diethyl ether, ethanol, glycerol and benzyl alcohol according to a proportion to obtain a first mixture;
mixing the components in the traditional Chinese medicine composition according to a proportion to obtain a second mixture;
and mixing the first mixture and the second mixture, processing, and filtering to obtain the medicine for treating alopecia areata.
9. The method of claim 8, wherein the steps of mixing the first mixture and the second mixture, processing, and filtering to obtain a medicament for treating alopecia areata include:
and standing the fully dissolved first mixture for 24-48 hours, then adding the second mixture, fully stirring, stirring once every 12-16 days, sealing, standing for 80-100 days, and filtering to obtain the medicine for treating alopecia areata.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310027290.8A CN116077557B (en) | 2023-01-09 | 2023-01-09 | Composition for treating alopecia areata and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310027290.8A CN116077557B (en) | 2023-01-09 | 2023-01-09 | Composition for treating alopecia areata and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116077557A true CN116077557A (en) | 2023-05-09 |
| CN116077557B CN116077557B (en) | 2024-04-26 |
Family
ID=86213387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310027290.8A Active CN116077557B (en) | 2023-01-09 | 2023-01-09 | Composition for treating alopecia areata and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116077557B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101415465A (en) * | 2006-03-31 | 2009-04-22 | 万能药生物有限公司 | Novel compositions for hair disorders and process of preparation thereof |
| CN101874866A (en) * | 2009-12-23 | 2010-11-03 | 泰一和浦（北京）中医药研究院有限公司 | External Chinese medicinal composition for treating calvities and alopecia areata and preparation method thereof |
| CN104490935A (en) * | 2014-12-10 | 2015-04-08 | 百花医药集团股份有限公司 | Application of compound Chinese gall salicylic acid preparation in preparation of medicine used for treating alopecia |
| KR101516536B1 (en) * | 2015-01-13 | 2015-05-04 | 주식회사 엔제이와이생명공학 | Composition for Preventing Hair Loss and Promoting Hair Growth and A method for manufacturing thereof |
| CN106362060A (en) * | 2016-11-22 | 2017-02-01 | 郑州润奇科技有限公司 | Traditional Chinese medicine stock solution for treating dandruff |
| CN111991431A (en) * | 2020-08-26 | 2020-11-27 | 陈广生 | A liniment for treating alopecia areata and its preparation method |
| CN112402615A (en) * | 2020-11-11 | 2021-02-26 | 长沙晶易医药科技有限公司 | Compound external preparation for treating alopecia areata and preparation method thereof |
| CN113509420A (en) * | 2021-08-10 | 2021-10-19 | 郑州润奇科技有限公司 | Process for treating seborrheic alopecia by KPT (KPT-based natural immunotherapy) |
| CN114392303A (en) * | 2022-02-17 | 2022-04-26 | 浙江卫未生物医药科技有限公司 | Exosome mixture for treating alopecia areata |
-
2023
- 2023-01-09 CN CN202310027290.8A patent/CN116077557B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101415465A (en) * | 2006-03-31 | 2009-04-22 | 万能药生物有限公司 | Novel compositions for hair disorders and process of preparation thereof |
| CN101874866A (en) * | 2009-12-23 | 2010-11-03 | 泰一和浦（北京）中医药研究院有限公司 | External Chinese medicinal composition for treating calvities and alopecia areata and preparation method thereof |
| CN104490935A (en) * | 2014-12-10 | 2015-04-08 | 百花医药集团股份有限公司 | Application of compound Chinese gall salicylic acid preparation in preparation of medicine used for treating alopecia |
| KR101516536B1 (en) * | 2015-01-13 | 2015-05-04 | 주식회사 엔제이와이생명공학 | Composition for Preventing Hair Loss and Promoting Hair Growth and A method for manufacturing thereof |
| CN106362060A (en) * | 2016-11-22 | 2017-02-01 | 郑州润奇科技有限公司 | Traditional Chinese medicine stock solution for treating dandruff |
| CN111991431A (en) * | 2020-08-26 | 2020-11-27 | 陈广生 | A liniment for treating alopecia areata and its preparation method |
| CN112402615A (en) * | 2020-11-11 | 2021-02-26 | 长沙晶易医药科技有限公司 | Compound external preparation for treating alopecia areata and preparation method thereof |
| CN113509420A (en) * | 2021-08-10 | 2021-10-19 | 郑州润奇科技有限公司 | Process for treating seborrheic alopecia by KPT (KPT-based natural immunotherapy) |
| CN114392303A (en) * | 2022-02-17 | 2022-04-26 | 浙江卫未生物医药科技有限公司 | Exosome mixture for treating alopecia areata |
Non-Patent Citations (1)
| Title |
|---|
| 崔新民: "斑秃的辨证论治", 浙江中医学院学报, vol. 13, no. 1, pages 131 - 144 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116077557B (en) | 2024-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69312942T2 (en) | COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE SAPONIN VOMGINSENOSIDE TYPE FOR HAIR CARE | |
| CN108938485B (en) | Hair growth liquid for preventing alopecia and preparation method thereof | |
| CN107970128B (en) | Formula and production process of hair growth promoting liquid containing diaminopyrimidine oxide | |
| DE69717968T2 (en) | Cosmetic or dermatological preparations containing peroxide lipids and organosilicon compounds and use thereof | |
| CN112870333A (en) | Composition and preparation for improving alopecia and promoting hair growth of human, and preparation method and application thereof | |
| WO1997042964A1 (en) | Method and product for promoting hair growth and treating skin conditions | |
| CN113368212A (en) | External traditional Chinese medicine and composition for treating alopecia and hair growth tincture containing external traditional Chinese medicine composition | |
| US20070116664A1 (en) | Methods and compositions for treating hair and skin afflictions | |
| CN114588060A (en) | Whitening and moisturizing mask with acne removing effect and preparation method thereof | |
| DE3853884T2 (en) | COMBINATION OF MINOXIDIL AND AN ANTI-INFLAMMATORY SUBSTANCE FOR THE TREATMENT OF ALOPECIA. | |
| CN116077557B (en) | Composition for treating alopecia areata and application thereof | |
| DE69330429T2 (en) | METHOD FOR TREATING HAIR LOSS | |
| CN116392422A (en) | Hair-growing and oil-controlling herbal composition and preparation method and application thereof | |
| JPH11269043A (en) | Cosmetic for scalp and hair | |
| JPH11269042A (en) | Cosmetic for scalp and hair | |
| CN114848569A (en) | Formula and preparation method of hair loss prevention and hair nourishing product | |
| CN110812410A (en) | External essential oil of radix codonopsis pilosulae and cortex cinnamomi for treating alopecia and promoting hair growth | |
| EP3638198A1 (en) | Composition for preventing hair loss and promoting hair growth | |
| JPH03167113A (en) | Hair regenerating agent | |
| JPH11302133A (en) | Cosmetic for scalp and hair | |
| KR101155502B1 (en) | Oriental hair restorer and the method using the same | |
| EP0319058A1 (en) | Hair growth composition | |
| JP3382148B2 (en) | External preparation for head | |
| CN108451828A (en) | It is a kind of to be used to treat hair nourishing liquid of alopecia seborrheica and preparation method thereof | |
| CN1150043A (en) | Efficient low-side effect external use medicine for curing seborrheic baldness |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |